Abbott/AstraZeneca's Certriad Bounced By FDA; ACCORD May Be The Culprit
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA for the TriLipix/Crestor combination drug is the subject of an FDA "complete response" letter.